Journal of the Endocrine Society Journal Article

Safety and Efficacy of Pressure-Enabled Thyroid Embolization

September 09, 2025

A Novel Approach for Symptomatic Thyroid Disease

 

Sandra Gad, Nima Kokabi, Michael Mohnasky, Ralph P Tufano, Angela Boldo, Juan C Camacho
Journal of the Endocrine Society, Volume 9, Issue 9, September 2025, bvaf117
https://doi.org/10.1210/jendso/bvaf117

Abstract

Context

To assess the safety and efficacy of pressure-enabled thyroid embolization (PED-TAE) for thyroid embolization.

Objective

This work aimed to evaluate the safety, feasibility, and early efficacy of PED-TAE via the inferior thyroid arteries in patients with symptomatic thyroid disease.

Methods

This retrospective cohort study took place at an academic outpatient clinic. Between May 2023 and July 2024, 22 patients underwent PED-TAE using a pressure-enabled drug delivery (PEDD) device. We retrospectively reviewed patient characteristics, procedure details, and adverse events. Patients were treated with PED-TAE predominantly via transradial access with 100 to 300 µm spheres. Ten patients (45%) underwent preplanned unilateral embolization and 12 (55%) bilateral embolization. Main outcome measures included successful embolization of the targeted thyroid lobe via an inferior thyroid artery only, as well as absence of nontarget embolization, target volume reduction, and normalization of thyroid function when appropriate.

Results

Etiology included 11 (50%) multinodular goiters, 6 (27%) toxic nodules/goiters, 3 (14%) pre thyroidectomy, 1 (4%) Graves disease, and 1 (4%) solitary nodule. Technical and clinical success was achieved in all patients. Eighteen patients reported mild pain or discomfort, which resolved within 2 weeks. No neurovascular complications were reported. A total of 71% of patients with hyperthyroidism became euthyroid. Six-month follow-up data were available for 18 patients, in whom the mean gland volume decreased from 184.5 ± 141.4 mL pre procedure to 49.9 ± 33.7 mL (P < .05), with a mean reduction of 73%.

Conclusion

PED-TAE is safe and feasible, with high euthyroid conversion rates and volume reduction. A multi-institutional study is planned to validate the findings.

Read the article

 

You may also like...

Publishing Benefits

Author Resource Center

We provide our journal authors with a variety of resources for increasing the discoverability and citation of their published work. Use these tools and tips to broaden the impact of your article.
Publishing Benefits

Author Resource Center

We provide our journal authors with a variety of resources for increasing the discoverability and citation of their published work. Use these tools and tips to broaden the impact of your article.

Thematic Issue

Latest Thematic Issue

immuno-endocrinology
Read our special collections of Endocrine Society journal articles, curated by topic, Altmetric Attention Scores, and Featured Article designations.

Read our special collections of Endocrine Society journal articles, curated by topic, Altmetric Attention Scores, and Featured Article designations.

Back to top

Who We Are

For 100 years, the Endocrine Society has been at the forefront of hormone science and public health. Read about our history and how we continue to serve the endocrine community.